Concepedia

Ilan Yanuv

IY

Statistics

Publications

19

Citations

1.9K

H-Index

17

Active since

2015

Affiliations

Hebrew University of Jerusalem(Current)

Hadassah Medical Center

Brigham and Women's Hospital

Thrombolysis in Myocardial Infarction Study Group

AstraZeneca (Sweden)

Ilan Yanuv is an author at Hebrew University of Jerusalem specializing in medicine, diabetes mellitus, and diabetology.

Publications per year

2015–2023

19

Publications

19

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn et al. · The Lancet Diabetes & Endocrinology · 2019 · 675 citations · Full text

, , +14

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Ofri Mosenzon, Gil Leibowitz, Deepak L. Bhatt et al. · Diabetes Care · 2016 · 270 citations

, , +12

Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes

Marianna Yaron, Eytan Roitman, Genya Aharon‐Hananel et al. · Diabetes Care · 2019 · 215 citations

, , +16

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Avivit Cahn, Ofri Mosenzon, Aliza Rozenberg et al. · Diabetes Care · 2019 · 131 citations

, , +15

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Ofri Mosenzon, Stephen D. Wiviott, Hiddo J.L. Heerspink et al. · Diabetes Care · 2021 · 109 citations · Full text

, , +17

1–5 of 19